Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

BACKGROUND: Clinical responses to EGFR tyrosine kinase inhibitors (TKIs) are restricted to tumors harboring specific activating mutations and even then, not all tyrosine kinase inhibitors provide clinical benefit. All TKIs however, effectively inhibit EGFR phosphorylation regardless of the mutation...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EBioMedicine
Hlavní autoři: de Wit, Maurice, Gao, Ya, Mercieca, Darlene, de Heer, Iris, Valkenburg, Bart, van Royen, Martin E., Aerts, Joachim, Sillevis Smitt, Peter, French, Pim
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2020
Témata:
Research paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7276512/
https://ncbi.nlm.nih.gov/pubmed/32512509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102796
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky